RxDoctor Payments Data

Richard Han, MD

Internal Medicine · Buena Park, CANPI 1821061466

Payments from drug & device makers

$76,317in general payments, 2019–2025

Across 1,404 payments — averaging $54.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$38K
  • Johnson & Johnson$14K
  • AbbVie$4K
  • Idorsia Pharmaceuticals US Inc$2K
  • Boehringer Ingelheim$2K
  • AstraZeneca$1K
  • plus $15K from 46 others

What the payments were for

  • Speaking & faculty fees$47,38362%
  • Travel & lodging$2,1213%
  • Food & beverage$26,71035%
  • Education$1030%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,317 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$66,045
Medicare patients
93
Services billed
902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin279$246,326
FarxigaDapagliflozin Propanediol214$179,124
OzempicSemaglutide146$176,108
KerendiaFinerenone150$147,627
JanuviaSitagliptin Phosphate172$120,162
VascepaIcosapent Ethyl239$109,530
ZenpepLipase/Protease/Amylase39$93,767
Repatha SureclickEvolocumab74$63,727
InvokanaCanagliflozin49$59,045
EntrestoSacubitril/Valsartan47$58,283
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$56,418
MounjaroTirzepatide39$42,976
CreonLipase/Protease/Amylase34$41,050
LinzessLinaclotide57$40,620
EliquisApixaban38$35,950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$1,710$267,246308 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$1,396$201,508253 claims
Novo NordiskOzempic$886$176,108146 claims
BayerKerendia$701$147,627150 claims
MerckJanuvia, Janumet, Belsomra$472$147,607205 claims
AbbVieCreon, Linzess, Namzaric, Viberzi$4,182$131,156139 claims
Aimmune Therapeutics, Inc.Zenpep$57$93,76739 claims
Johnson & JohnsonInvokana, Xarelto$13,926$82,40678 claims
NovartisEntresto$545$58,28347 claims
GSKTrelegy Ellipta$998$56,41861 claims
Lilly USA, LLCMounjaro$878$42,97639 claims
PfizerEliquis$704$35,95038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Buena Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →